CLINICAL TRIALS AND OBSERVATIONS Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome
نویسندگان
چکیده
1Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan; 2Laboratory of Clinical, Epidemiological and Health Services Research, National Hospital Organization, Nagoya Medical Center Clinical Research Center, Aichi, Japan; 3Department of Hematology/Oncology, Shizuoka Children’s Hospital, Shizuoka, Japan; 4Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan; 5Department of Pediatrics, Hirosaki University Graduate School of Medicine, Aomori, Japan; 6Department of Reproductive and Developmental Medicine, Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; 7Department of Pediatrics, St Marianna University School of Medicine, Kanagawa, Japan; 8Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan; 9Department of Pediatrics, National Hospital Organization, Fukuoka-Higashi Medical Center, Fukuoka, Japan; 10Department of Pediatrics, Saiseikai Yokohama City Southern Hospital, Kanagawa, Japan; 11Department of Pediatrics, National Hospital Organization, Osaka Medical Center, Osaka, Japan; 12Department of Pediatrics, Nagoya University Graduate School of Medicine, Aichi, Japan; 13Department of Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan; 14Department of Hematology/Oncology, Kanagawa Children’s Medical Center, Kanagawa, Japan; 15Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan; and 16Human Health Sciences, Kyoto University, Kyoto, Japan
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 in...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study
We assessed the outcome of children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) receiving contemporary risk-based therapy by evaluating clinical and biologic features and outcome of children with ALL, with or without DS, enrolled in Children’s Cancer Group (CCG) protocols between 1983 and 1995. Comparison of characteristics of children with ALL with (ALL-DS; n 179) or without...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
1From the Service d’Hématologie, Hôtel Dieu, Nantes, France; 2H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa; 3Service des Maladies du Sang, Hôpital du Haut Leveque, Pessac, France; 4Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; 5Service des Maladies du Sang, Hôpital Edouard Herriot, Lyon, France; 6Service d’Hémat...
متن کاملAuthentic caring occasions for patients in hairy cell leukemia clinical trials.
BACKGROUND Rare diseases present challenges for patients, healthcare providers, and researchers. Rare disease communities exist for collaboration, dissemination of information, and to promote support for all community members. Patients with a rare disease desire to be supported through a rare disease community. Hairy cell leukemia (HCL) is a rare adult B-cell lymphocytic cancer that currently h...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 acute myeloid leukemia
This open-label, dose-escalation study evaluated the safety and efficacy of singleagent gemtuzumab ozogamicin, a humanized anti-CD33 antibody–targeted chemotherapeutic agent, for pediatric patients with multiple relapsed or primary refractory acute myeloid leukemia (AML). Twenty-nine children 1 to 16 years of age (relapsed disease, 19; refractory disease, 10) received gemtuzumab ozogamicin rang...
متن کامل